ADC Therapeutics Ltd ADCT 深 滬
已收盤 05-22 16:00:00 美东时间
3.39
-0.010
-0.29%
華盛通- 最 高3.45
- 今 開3.41
- 成交量 64.85万股
- 最 低 3.355
- 昨 收 3.40
- 總市值 4.31亿
- 52周最高 4.98
- 市盈率 靜 --
- 換手率 0.51%
- 52周最低 2.55
- 委 比 -37.95%
- 總股本 1.27亿
- 歷史最高 56.59
- 量 比 0.66
- 振 幅 2.79%
- 歷史最低 0.3599
- 每 手 1
- 風險率 0.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $8 price target.
05-05 18:38
电话会总结 ｜ ADC Therapeutics(ADCT)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据ADC Therapeutics业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 2025年第四季度净产品收入为2,230万美元，同比增长35.98%（2024年同期为1,640万美元） - 2025年全年净产品收入为7,360万美元，同比增长6.19%（2024年为6,930万美元） - 全年收入增长主要由净价格调整驱动，基础销量基本持平 **盈利状况：** - 2025年第四季度净亏损640万美元（每股亏损0.04美元），同比大幅改善79.15%（2024年同期净亏损3,070万美元，每股亏损0.29美元）
05-05 12:05
ADC Therapeutics Balances Solid Quarter With Trial Risk
ADC Therapeutics Ltd (($ADCT)) has held its Q1 earnings call. Read on for the m...
05-05 08:24
Full Transcript: ADC Therapeutics Q1 2026 Earnings Call
ADC Therapeutics (NYSE:ADCT) held its first-quarter earnings conference call on...
05-05 04:48
ADC Therapeutics Q1 Adj. EPS $(0.13) Beats $(0.21) Estimate, Sales $20.851M Beat $19.240M Estimate
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.21) by 38.1 percent. This is a 40.91 percent increase over losses of $(0.22) per share from the
05-04 19:58
Earnings Scheduled For May 4, 2026
Companies Reporting Before The Bell • Pulse Biosciences (NASDAQ:PLSE) is likely...
05-04 19:11
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today annou...
05-01 16:05
ADC Therapeutics Earnings Call: Trials, Cash And Risks
ADC Therapeutics Ltd (($ADCT)) has held its Q4 earnings call. Read on for the m...
04-04 08:07
ADC Therapeutics Announces New Employee Inducement Grant
LAUSANNE, Switzerland, April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today ann...
04-02 04:05
